Status:

COMPLETED

Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus

Lead Sponsor:

Chinese University of Hong Kong

Conditions:

Systemic Lupus Erythematosus

Eligibility:

FEMALE

18-80 years

Phase:

PHASE4

Brief Summary

The primary aim of the present study was to investigate the prevalence of low bone mineral density (BMD) and vertebral fractures, as determined by a standardized assessment, and to elucidate the role ...

Detailed Description

In the first part of the study, 150 consecutive patients with a diagnosis of SLE were included in the study. All patients fulfilled the American College of Rheumatology (ACR) revised criteria for the ...

Eligibility Criteria

Inclusion

  • Part I
  • Fulfilled the ACR revised criteria for the classification of SLE
  • Provided written informed consent for their participation
  • Part II
  • Have low BMD (T socre \< -1 S.D. at the lumbar spine (L1-L4) or total hip) induced by the long-term administration of high-dose corticosteroids.
  • Had been receiving chronic uninterrupted corticosteroid therapy for at least 1 year or had received a corticosteroid dose of at least 5 mg/day.

Exclusion

  • Hypocalcaemia, hypercalcaemia, Hypercalciuria, a creatinine clearance of less than 30 ml per minute.
  • A history of nephrolithiasis during the previous five years.
  • A history of recent major gastrointestinal (GI) tract disease (e.g. oesophagitis).
  • Had or presence of primary hyperparathyroidism, hyperthyroidism, or hypothyroidism in the year before the study began.
  • Had experienced any previous adverse reaction to bisphosphonate therapy (alendronate, fosamax, ibandronate).
  • With uncontrolled active or recurrent peptic ulcer disease.
  • Receiving therapy (within the last 6 months) known to affect bone metabolism, including:hormone-replacement agents, calcitonin, active vitamin D3 analogues, thiazide diuretics,treatment with bisphosphonates,fluoride treatment within the last 12 mons or for a total duration of 2 years; contraindications to calcium or vitamin D therapy.
  • Pregnant or breastfeeding.

Key Trial Info

Start Date :

April 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2009

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT00668330

Start Date

April 1 2007

End Date

May 1 2009

Last Update

February 13 2012

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

School of Pharmacy CUHK

Hong Kong, China